# US 2019/0375810 A1 · Use of erythropoietin-derived peptide through effect on cell damage prevention thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375810 A1
- Document ID: US20190375810A1
- Status: Published application
- Kind: A1
- Application number: 16/551,060
- Filed: 2019-08-26
- Published: 2019-12-12
- Earliest claimed: 2017-02-27
- Assignees: Daegu Gyeongbuk Institute of Science and Technology
- Applicants: Daegu Gyeongbuk Institute of Science and Technology
- Inventors: Che il MOON; Seung Jun YOO; Chang-Hun LEE; So Yeon KIM; Deok Ho LEE
- Web page: https://patentgrep.com/patent/US20190375810A1

## CPC

- C07K 14/505: Erythropoietin [EPO]
- A61K 38/1816: {Erythropoietin [EPO]}
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/1709: {from mammals}
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/6031: {Proteins}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/435: from animals; from humans
- C07K 14/47: from mammals
- C07K 14/4705: {stimulating, promoting or activating activity}
- C07K 14/71: for growth factors; for growth regulators
- C07K 2319/00: Fusion polypeptide
- C07K 2319/70: containing domain for protein-protein interaction
- C12N 15/85: for animal cells
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- G01N 33/5044: {involving specific cell types}
- G01N 33/5058: {Neurological cells}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A peptide is described herein that has: (i) a simple structure compared to existing natural human erythropoietin, thus capable of easily passing through a tissue-blood barrier, (ii) excellent bioactivity with respect to cell-protecting activity, (iii) a low manufacturing cost, thus being economically advantageous, and (iv) no side effects on cell proliferation. Also, a pharmaceutical composition comprising the erythropoietin-derived peptide described herein as an active ingredient is described. The pharmaceutical composition may be used for preventing or treating cell damage-related illnesses, such as stroke, mechanical damage or ischemic damage to the nervous system, myocardial infarction, retinal damage, and diabetes. Also, the described pharmaceutical composition may be used for preventing cell damage.

## Claims

### Claim 1

A peptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 25.

### Claim 2 (depends on 1)

The peptide of claim 1, wherein the peptide is derived from an erythropoietin protein sequence.

### Claim 3 (depends on 1)

The peptide of claim 1, wherein the peptide binds to an erythropoietin receptor.

### Claim 4 (depends on 1)

The peptide of claim 1, wherein the peptide forms an alpha-helical structure.

### Claim 5 (depends on 1)

The peptide of claim 1, wherein the peptide exhibits cell protective activity.

### Claim 6 (depends on 1)

The peptide of claim 1, wherein the peptide has no side effects of cell proliferation.

### Claim 7 (depends on 1)

A pharmaceutical composition for preventing or treating a neurodegenerative disease, the pharmaceutical composition comprising,
as an active ingredient, the peptide of claim 1, one or more polynucleotides encoding the peptide, a vector comprising the one or more polynucleotides, or a host cell comprising the vector.

### Claim 8 (depends on 7)

The pharmaceutical composition for preventing or treating a neurodegenerative disease of claim 7, wherein the neurodegenerative disease is any one selected from the group consisting of stroke, paralysis, myocardial infarction, dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, Pick's disease, and Creutzfeldt-Jakob disease.

### Claim 9 (depends on 7)

The pharmaceutical composition for preventing or treating a neurodegenerative disease of claim 7, wherein the host cell is an HEK-293E cell, a Chinese hamster ovary (CHO) cell, a baby hamster kidney (BHK) cell, an NIH-3T3 cell, an HEK-293T cell, or a COS-7 cell.

### Claim 10 (depends on 7)

The pharmaceutical composition for preventing or treating a neurodegenerative disease of claim 7, wherein the vector is a linear DNA vector, a plasmid DNA vector, or a recombinant viral vector.

### Claim 11 (depends on 10)

The pharmaceutical composition for preventing or treating a neurodegenerative disease of claim 10, wherein the recombinant viral vector is any one selected from the group consisting of retroviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, and lentiviruses.

### Claim 12 (depends on 1)

A method of preventing or treating a neurodegenerative disease, the method comprising:
administering a composition comprising, as an active ingredient, the peptide of claim 1, one or more polynucleotides encoding the peptide, a vector comprising the one or more polynucleotides, or a host cell comprising the vector.

### Claim 13 (depends on 1)

Use of a composition comprising,
as an active ingredient, the peptide of claim 1, one or more polynucleotides encoding the peptide, a vector comprising the polynucleotide, or a host cell comprising the vector in the preparation of a prophylactic or therapeutic agent for a neurodegenerative disease.
